Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $9.07, for a total transaction of $199,540.00. Following the completion of the sale, the director owned 1,100,391 shares of the company’s stock, valued at $9,980,546.37. This represents a 1.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded up $0.08 during trading on Thursday, reaching $9.10. 851,331 shares of the company traded hands, compared to its average volume of 3,500,792. The firm has a market capitalization of $1.27 billion, a PE ratio of -2.88 and a beta of 1.66. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $10.94. The company has a 50 day moving average price of $8.45 and a 200-day moving average price of $6.79.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. During the same period in the previous year, the firm posted ($0.76) earnings per share. The business’s revenue was up 417.8% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Trading of Vir Biotechnology

Several institutional investors have recently made changes to their positions in VIR. AQR Capital Management LLC raised its holdings in shares of Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Vir Biotechnology during the first quarter worth about $359,000. Goldman Sachs Group Inc. grew its position in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP increased its stake in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after buying an additional 331,701 shares during the last quarter. Finally, Focus Partners Wealth increased its stake in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after buying an additional 2,566 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Evercore reissued an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, February 24th. HC Wainwright upped their target price on Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target for the company in a research report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Finally, Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.44.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.